Results 211 to 220 of about 33,240 (248)
Some of the next articles are maybe not open access.
Enfuvirtide: A fusion inhibitor for the treatment of HIV infection
Clinical Therapeutics, 2004Drug resistance continues to be a major challenge in the treatment of HIV-1 infection. Virtually all currently available antiretroviral medications inhibit the viral reverse transcriptase or protease. Enfuvirtide is the first fusion inhibitor approved by the US Food and Drug Administration for use in combination with other antiretroviral agents for the
Horatio B, Fung, Yi, Guo
openaire +2 more sources
Sifuvirtide, a potent HIV fusion inhibitor peptide
Biochemical and Biophysical Research Communications, 2009Enfuvirtide (ENF) is currently the only FDA approved HIV fusion inhibitor in clinical use. Searching for more drugs in this category with higher efficacy and lower toxicity seems to be a logical next step. In line with this objective, a synthetic peptide with 36 amino acid residues, called Sifuvirtide (SFT), was designed based on the crystal structure ...
Rui-Rui, Wang +6 more
openaire +2 more sources
Peptide and Non-peptide HIV Fusion Inhibitors
Current Pharmaceutical Design, 2002Fusion of the HIV envelope with the target cell membrane is a critical step of HIV entry into the target cell. The HIV envelope glycoprotein gp41 plays an important role in the fusion of viral and target cell membranes and serves as an attractive target for development of HIV fusion inhibitors.
Shibo, Jiang +2 more
openaire +2 more sources
Are Fusion Inhibitors Active against All HIV Variants?
AIDS Research and Human Retroviruses, 2004Genetic sequence alignment of the transmembrane region from HIV-1 group O and HIV-2 isolates was performed to examine their potential susceptibility to fusion inhibitors enfuvirtide (T-20) and T-1249. A high genetic diversity within the HRI and HR2 domains was found, which should compromise any antiviral effect of T-20 on HIV-2 and HIV-1 group O ...
Eva, Poveda +3 more
openaire +2 more sources
Enfuvirtide: first fusion inhibitor for treatment of HIV infection
American Journal of Health-System Pharmacy, 2004The mechanism of action, pharmacokinetics, clinical efficacy, adverse effects, and availability of enfuvirtide are discussed.To date, 20 antiretrovirals have been approved by FDA for the treatment of HIV infection. The recent approval of enfuvirtide offers a new and fourth class of antiretroviral agents called fusion inhibitors.
M Christine, Jamjian, Ian R, McNicholl
openaire +2 more sources
Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide
Journal of Theoretical Biology, 2011Recently, the first drug in a new class of antiretroviral HIV drugs was approved, the fusion inhibitor enfuvirtide. We develop a mathematical model that describes the binding of the virus to T cells. We model the effect of enfuvirtide upon this process using impulsive differential equations.
Lou, Jie, Smith, Robert J
openaire +2 more sources
Enfuvirtide: The first fusion inhibitor for HIV
Practice Nursing, 2005Emma MacFarlane explains the action of a new antiretroviral for HIV and considers the nurse's role in patient education and support
openaire +1 more source
The peptides and peptidomimetics: HIV-1 fusion inhibitors
SCIENTIA SINICA Chimica, 2013The fusion of HIV and target cell membranes is mediated by the transmembrane glycoprotein gp41. HIV-1 fusion inhibitors target gp41 to prevent the virus-cell membrane fusion, thus interrupt the initial steps of viral replication. The first peptide fusion inhibitor (T-20) was approved by the U.S. FDA in 2003. However, the application of T-20 was limited
QiYan JIA, KeLiang LIU, LiFeng CAI
openaire +1 more source
Peptide HIV fusion inhibitors: modifications and conjugations
Med. Chem. Commun., 2014HIV fusion inhibitors are a group of virus entry preventing drugs aimed at membrane fusion.
Wei Liu +4 more
openaire +1 more source
The development of a new fusion inhibitor for the treatment of HIV
2017Since the introduction of combination antiretroviral therapy (ART), there has been a dramatic improvement in the prognosis of people living with HIV. Indeed, data from numerous cohorts now show that for people commenced on ART at high CD4 counts and who are retained in care, life expectancy is similar to matched HIV-negative people.
openaire +2 more sources